Statins of different brain penetrability differentially affect CSF PLTP activity

Dementia and Geriatric Cognitive Disorders

Volumn 22, Issue 5-6, 2006, Pages 392-398

  Vuletic, Simona ^a   Riekse, Robert G ^a   Marcovina, Santica M ^a   Peskind, Elaine R ^a,b   Hazzard, William R ^a   Albers, John J ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Education   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apolipoprotein E; Blood brain barrier; Cerebrospinal fluid; PLTP activity; Statins

Indexed keywords

AMINOTRANSFERASE; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID TRANSFER PROTEIN; PRAVASTATIN; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PERMEABILITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; BLOOD-BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEMENTIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHOLIPID TRANSFER PROTEINS; TIME FACTORS;

EID: 33750899291     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095679     Document Type: Article

References (60)

1. Roheim PS, Carey M, Forte T, Vega GL: Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979;76:4646-4649.
2. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
3. Boyles JK, Notterpek LM, Anderson LJ: Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. J Biol Chem 1990;265:17805-17815.
4. Poirier J, Baccichet A, Dea D, Gauthier S: Cholesterol synthesis and lipoprotein reuptake during synaptic remodeling in hippocampus in adult rats. Neuroscience 1993;55:81-90.
5. Masliah E, Samuel W, Veinbergs I, Mallory M, Mante M, Saitoh T: Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res 1997;751:307-314.
6. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, Lendon CL, Han SW, Morris JC, Vazquez J, Goate A, Valdivieso F: Risk of Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 1998;7:1887-1892.
7. Davidsson P, Sjögren M, Andreasen N, Lindbjer M, Nilsson CL, Westman-Brinkmalm A, Blennow K: Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 2002;109:128-133.
8. Champagne D, Pearson D, Dea D, Rochford J, Poirier J: The cholesterol-lowering drug Probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 2003;121:99-110.
9. Poirier J: Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005;26:355-361.
10. Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J: Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome. Stroke 2003;34:637-642.
11. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM: ApoE and clusterin cooperatively suppress Aβ levels and deposition: Evidence that apoE regulates extracellular Aβ metabolism in vivo. Neuron 2004;41:193-202.
12. Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, Manelli A, LaDu MJ, Hyman BT, Rebeck GW: Apolipoprotein E modulates γ-secretase cleavage of the amyloid precursor protein. J Neurochem 2004;90:1132-1143.
13. Lahiri DK: Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA and regulatory region of the gene. J Mol Neurosci 2004;23:225-233.
14. Champagne D, Rochford J, Poirier J: Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response. Exp Neurol 2005;194:31-42.
15. Werner N, Nickenig G, Laufs U: Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002;97:106-116.
16. Miida T, Hirayama S, Nakamura Y: Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 2004;11:253-264.
17. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-987.
18. Nishikawa O, Mune M, Miyaho M, Nishide T, Nishide I, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S: Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int Suppl 1999;71:S219-S221.
19. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000;49:167-177.
20. Kobayashi J, Maruyama T, Masuda M, Shinomiya M: Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta 2001;314:261-264.
21. Bach-Ngohou K, Ouguerram K, Frenais R, Maugere P, Ripolles-Piquier B, Zair Y, Krempf M, Bard JM: Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. J Pharmacol Exp Ther 2005;315:363-369.
22. Hoglund K, Thelen KM, Syversen S, Sjögren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lutjohann D, Blennow K: The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:256-265.
23. Botti RE, Triscari J, Pan HY, Zayat J: Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991;14:256-261.
24. Saheki A, Terasaki T, Tamai I, Tsuji A: In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994;11:305-311.
25. Vuletic S, Peskind ER, Marcovina SM, Quinn JF, Cheung MC, Kennedy H, Kaye JA, Jin LW, Albers JJ: Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J Neurosci Res. 2005;80:406-413.
26. Wolfbauer G, Albers JJ, Oram JF: Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta 1999;1439:65-76.
27. Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ: Phospholipid transfer protein interacts with and stabilizes ABCA1 and enhances cholesterol efflux from cells. J Biol Chem 2003;278:52379-52385.
28. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL: Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 2004;279:41197-411207.
29. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM: ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 2004;279:40987-40993.
30. Albers JJ, Wolfbauer G, Cheung MC, Day JR, Ching AF, Lok S, Tu AY: Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta 1995;1258:27-34.
31. Rao R, Albers JJ, Wolfbauer G, Pownall HJ: Molecular and macromolecular specificity of human plasma phospholipid transfer protein. Biochemistry 1997;36:3645-3653.
32. Kostner GM, Oettl K, Jauiainen M, Ehnholm C, Esterbauer H, Dieplinger H: Human plasma phospholipid transfer protein accelerates exchange/transfer of α-tocopherol between lipoproteins and cells. Biochem J 1995;305:659-667.
33. Desrumaux C, Risold PY, Schroeder H, Deckert V, Masson D, Athias A, Laplanche H, Guern NL, Blache D, Jiang XC, Tall A, Desor D, Lagrost L: Phospholipid transfer protein deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB J 2004;19:296-297.
34. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000;356:1627-1631.
35. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
36. Zamrini E, McGwin G, Roseman JM: Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-98.
37. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, Pasquier F: Lipid-lowering agents are associated with slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76:1624-1629.
38. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Bereuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB: Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-350.
39. Sjögren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K: Treatment with simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003;16:25-30.
40. Sparks Dl, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C: Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res 2005;2:343-353.
41. Folstein MF, Folstein SE, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
42. Flicker C, Ferris SH, Reisberg B: Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41:1006-1009.
43. Morris JC: Clinical Dementia Rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int J Psychogeriatr 1997;9:173-176.
44. Cheung MC, Wolfbauer G, Albers JJ: Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta 1996;1303:103-110.
45. 2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-1388.
46. Vuletic S, Jin LW, Marcovina SM, Peskind ER, Moller T, Albers JJ: Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease. J Lipid Res 2003;44:1113-1123.
47. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
48. Ray KK, Cannon CP: Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 2004;18:89-101.
49. Cucchiara B, Kasner SE: Use of statins in CNS disorders. J Neurol Sci 2001;187:81-89.
50. Stuve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS: Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets 2003;7:613-622.
51. Stuve O, Youssef S, Steinman L, Zamvil SS: Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003;16:393-401.
52. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, Schubert-Zsilavecz M, Karas M, Muller WE, Wood WG: Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. JPET 2005;312:786-793.
53. Cheung MC, Brown BG, Marino Larsen EK, Frutkin AD, O'Brien KD, Albers JJ: Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta 2005;1762:131-137.
54. De Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BH, van Tol A, Dullaart RP: Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2005;23:1-7.
55. Oomen PH, van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RP: Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in type 1 diabetes mellitus. Diabet Med 2005;22:768-774.
56. Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC: Anti-inflammatory effects of phospholipid transfer protein deficiency in mice. Biochim Biophys Acta 2005;1733:187-191.
57. Tan KC, Shiu SW, Wong Y, Tam S: Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005;178:365-370.
58. Valenta DT, Ogier N, Bradshaw G, Black AS, Bonnet DJ, Lagrost L, Curtiss LK, Desrumaux CM: Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioslcer Thromb Vasc Biol 2006;26:1572-1578.
59. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, Kauffman RF, Gao H, Ryan TP, Liang Y, Eacho PI, Jiang XC: Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002;277:39561-39565.
60. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM: A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 2004;88:623-634.